CeriBell (NASDAQ:CBLL) Director Joseph Michael Taylor Sells 13,095 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 13,095 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $23.40, for a total transaction of $306,423.00. Following the completion of the transaction, the director owned 48,478 shares in the company, valued at approximately $1,134,385.20. This trade represents a 21.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Joseph Michael Taylor also recently made the following trade(s):

• On Thursday, June 11th, Joseph Michael Taylor sold 5,500 shares of CeriBell stock. The shares were sold at an average price of $18.41, for a total transaction of $101,255.00.

CeriBell Stock Performance

Shares of NASDAQ:CBLL traded up $0.08 during midday trading on Friday, reaching $23.33. The company’s stock had a trading volume of 135,920 shares, compared to its average volume of 342,175. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The stock has a fifty day moving average of $18.83 and a 200 day moving average of $19.08. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33. The firm has a market capitalization of $895.21 million, a PE ratio of -13.21 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 43.02%. On average, equities analysts expect that CeriBell, Inc. will post -1.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its stake in CeriBell by 41.4% in the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after acquiring an additional 854 shares during the period. Sei Investments Co. lifted its holdings in CeriBell by 2.3% during the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock valued at $923,000 after purchasing an additional 1,125 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the period. Deutsche Bank AG grew its position in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the period. Finally, Strs Ohio purchased a new stake in shares of CeriBell during the first quarter worth about $27,000.

Analyst Ratings Changes

A number of research analysts have issued reports on CBLL shares. Canaccord Genuity Group boosted their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday. BTIG Research reiterated a “buy” rating and issued a $28.00 target price on shares of CeriBell in a research note on Tuesday. Finally, Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.